Categories: HealthcareNews

Health Catalyst Announces ~$5 Million Stock Repurchase

SALT LAKE CITY, March 11, 2025 /PRNewswire/ — Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has repurchased shares of its common stock (“Common Stock”) in an aggregate amount of approximately $5 million.

These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst’s existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to $40 million of Common Stock. These recent repurchases resulted in the retirement of approximately 1.1 million shares of Common Stock.

“Our repurchase of shares underscores our confidence in the future of our business,” said Dan Burton, CEO of Health Catalyst. “We believe the current market does not reflect the long-term value of our shares of common stock, including our anticipated continued achievement of operating leverage and our reacceleration of revenue growth. This repurchase demonstrates our continued commitment to creating long-term, sustainable value for our shareholders, our clients, and our team members.”

About Health Catalyst
Health Catalyst (Nasdaq: HCAT) is a leading provider of data and analytics technology and services that ignite smarter healthcare, lighting the path to measurable clinical, financial, and operational improvement. More than 1,000 organizations worldwide rely on Health Catalyst’s offerings, including our cloud-based technology ecosystem Health Catalyst Ignite™, AI-enabled data and analytics solutions, and expert services to drive meaningful outcomes across hundreds of millions of patient records. Powered by high-value data, standardized measures and registries, and deep healthcare domain expertise, Ignite helps organizations transform complex information into actionable insights. Backed by a multi-decade mission and a proven track record of delivering billions of dollars in measurable results, Health Catalyst continues to serve as the catalyst for massive, measurable, data-informed healthcare improvement and innovation.

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to Health Catalyst’s operating leverage, revenue growth and stock performance. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding Health Catalyst’s future performance and opportunities. These forward-looking statements represent Health Catalyst’s expectations as of the date of this press release, and involve risks, uncertainties and assumptions. The actual results may differ materially from those anticipated in the forward-looking statements as a result of numerous factors, many of which are beyond Health Catalyst’s control. Important risks and uncertainties that could cause Health Catalyst’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to Health Catalyst’s business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst’s technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners; (v) macroeconomic challenges (including high inflationary and/or high interest rate environments, or market volatility caused by bank failures and measures taken in response thereto) and any new public health crisis; and (vi) changes to Health Catalyst’s abilities to recruit and retain qualified team members. For a detailed discussion of the risk factors that could affect Health Catalyst’s actual results, please refer to the risk factors identified in Health Catalyst’s SEC reports, including, but not limited to the Annual Report on Form 10-K for the year ended December 31, 2024 filed on February 26, 2025, available at www.sec.gov. While Health Catalyst may elect to update such forward-looking statements at some point in the future, Health Catalyst disclaims any obligation to do so, even if subsequent events cause Health Catalyst’s views to change.

Investor Relations Contact:
Jack Knight
Vice President, Investor Relations
+1 (855)-309-6800
ir@healthcatalyst.com 

Media Contact:
Kathryn Mykleseth
PR and Communications Director
media@healthcatalyst.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/health-catalyst-announces-5-million-stock-repurchase-302397725.html

SOURCE Health Catalyst

Staff

Recent Posts

MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi

KARACHI, Pakistan, Dec. 22, 2025 /PRNewswire/ -- MindHYVE.ai, Inc., and Khoja (Pirhai) Shia Isna Asheri Jamaat…

3 hours ago

Castle Connolly Names Dr. Meegan Gruber, MD, PhD a 2026 Exceptional Woman in Medicine; Recognition to Be Featured in New York Magazine

Board-certified plastic surgeon and surgeon-scientist honored for clinical excellence, leadership, and commitment to patient education. …

3 hours ago

Planning Time Off in 2026: Dr. Meegan Gruber, MD, PhD Releases a Recovery-Logistics Guide for Busy Professionals Considering Plastic Surgery

New "Recovery Logistics" checklist helps patients coordinate work, childcare, travel, and follow-up support-before they choose…

3 hours ago

How to Choose a Plastic Surgeon in 2026: Dr. Meegan Gruber, MD, PhD Releases a Tampa Bay Patient Safety Checklist

Board-certified plastic surgeon shares a practical, question-based guide to help patients verify credentials, facility standards,…

3 hours ago

Facelift + Eyelid Surgery in Tampa: Gruber Plastic Surgery Shares 2025 Planning Insights on Natural Results and Popular Procedure Pairings

ASPS trend reporting highlights facelift combined with eyelid surgery as a leading 2025 combination; national…

3 hours ago

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI)…

6 hours ago